PUBLIC COMPANY
saveMemorial Sloan Kettering Cancer Center
updated 5mo ago
community read0 votes
🐶 often sniffed alongside
top 3pipeline
1
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 1
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2A Study of Mirdametinib in People With Central Nervous System Tumors
- phase2Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
- phase2Tislelizumab in People With Colorectal Cancer
- phase2Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
- phase1A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer
- phase1A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment
- phase3Using an Artificial Intelligence (AI) Tool for Melanoma Diagnosis
- phase2A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)
🐶 Hiring Signal
News
- American Cancer Society revises guidelines, urges routine PSA screening for prostate cancerThe American Cancer Society recommended routine PSA screening for prostate cancer, changing guidelines in place since 2010.stat · 1d ago
- STAT+: After a cancer vaccine’s first success, the race is on to expand the impactAfter 100 years, there's finally an effective cancer vaccine. Now comes the push to get them to work in more tumor types.stat · 19d ago
- FDA Approves Immunotherapy That May Allow Certain Patients with Rectal Cancer to Avoid Chemotherapy, Radiation and SurgeryThe U.S. Food and Drug Administration today granted accelerated approval for a new use of the immunotherapy Jemperli (dostarlimab-gxly) that may allow some patients with locally advanced rectal can…fda_press · 25d ago
- The 2026 Biotech GraveyardFierce’s biotech graveyard is an annual tradition in which we remember all the companies we lost over the past year. While we're embracing the spooky spirit of Halloween, we hope the sad stories of…fiercebiotech · 1mo ago
- 5 drugmakers chasing Merck and Moderna in the cancer vaccine raceFollowing their blowout win in melanoma last month, Merck and Moderna are leading the way among a new crop of personalized cancer vaccines. Here are five companies with similar therapies hoping to…biospace · 2mo ago
- After a brief storm of political headwinds, mRNA is back with strong momentumA year to the day after the Trump administration slashed $500 million in funding from mRNA-based programs, the FDA approved Moderna’s flu vaccine based on the technology. Weeks later, Moderna and M…biospace · 2mo ago
- Moderna and Merck’s mRNA success fuels focus on ‘scaling out and scaling down’After mastering mass-market mRNA production during the pandemic, the industry now needs to achieve the timely delivery of individualized vaccines to thousands of patients.biospace · 2mo ago
- BioNTech halts mid-stage trial of personalized mRNA vaccine in colorectal cancerShares of Germany-based BioNTech were down as much as 8% Friday after announcing a Phase 2 trial of autogene cevumeran would be discontinued for futility. The news follows Merck and Moderna’s Phase…biospace · 2mo ago
- Amgen, academic centers weigh new FDA pilot to speed early drug trialsTo better combat China and Australia's dominance in expediting early-phase trials, the FDA and stakeholders are ironing out the details of a pilot program to accelerate first-in-human trials. Amgen…endpoints · 2mo ago
- Third time’s the charm for Replimune as melanoma drug earns FDA greenlightReplimune’s immunotherapy for advanced melanoma faced a perilous regulatory road with two previous rejections, but the drug—to be marketed as Tudriqev—prevailed with strong support from oncologists…biospace · 3mo ago
comments(0)
5-min edit window · permanent after that